Comparison of patients surviving and succumbing to TA-GVHD
| Characteristics . | Dead (n = 312) . | Survived (n = 29) . | P . |
|---|---|---|---|
| Patient | |||
| Male, n (%) | 195 (62.5) | 13 (44.8) | .098 |
| Age, median (IQR) | 59 (20, 69) | 35 (5,50) | <.01 |
| Condition warranting irradiation, n (%) | 102 (32.7) | 17 (58.6) | .011 |
| Time to symptom onset, days, median (IQR) | 11 (9, 14) | 13 (8,23) | .42 |
| Component | |||
| Whole blood, n (%) | 89 (28.5) | 2 (6.9) | .012 |
| Leukoreduced component,* n (%) | 16 (5.1) | 6 (20.7) | .013 |
| Component age ≤48 hours or fresh, n (%) | 81 (26.0) | 2 (6.9) | .026 |
| Component age >10 days, n (%) | 9 (2.9) | 1 (3.4) | — |
| Treatment | |||
| Immunosuppression, n (%) | 156 (50) | 16 (55.2) | .74 |
| Steroids, n (%) | 142 (45.5) | 15 (51.7) | .65 |
| Cyclosporin, n (%) | 34 (10.9) | 3 (10.3) | .98 |
| IVIg, n (%) | 19 (6.1) | 4 (13.8) | .24 |
| ATG/ALG, n (%) | 33 (10.6) | 0 (0) | — |
| Bone marrow transplant, n (%) | 5 (1.6) | 3 (10.3) | .046 |
| Characteristics . | Dead (n = 312) . | Survived (n = 29) . | P . |
|---|---|---|---|
| Patient | |||
| Male, n (%) | 195 (62.5) | 13 (44.8) | .098 |
| Age, median (IQR) | 59 (20, 69) | 35 (5,50) | <.01 |
| Condition warranting irradiation, n (%) | 102 (32.7) | 17 (58.6) | .011 |
| Time to symptom onset, days, median (IQR) | 11 (9, 14) | 13 (8,23) | .42 |
| Component | |||
| Whole blood, n (%) | 89 (28.5) | 2 (6.9) | .012 |
| Leukoreduced component,* n (%) | 16 (5.1) | 6 (20.7) | .013 |
| Component age ≤48 hours or fresh, n (%) | 81 (26.0) | 2 (6.9) | .026 |
| Component age >10 days, n (%) | 9 (2.9) | 1 (3.4) | — |
| Treatment | |||
| Immunosuppression, n (%) | 156 (50) | 16 (55.2) | .74 |
| Steroids, n (%) | 142 (45.5) | 15 (51.7) | .65 |
| Cyclosporin, n (%) | 34 (10.9) | 3 (10.3) | .98 |
| IVIg, n (%) | 19 (6.1) | 4 (13.8) | .24 |
| ATG/ALG, n (%) | 33 (10.6) | 0 (0) | — |
| Bone marrow transplant, n (%) | 5 (1.6) | 3 (10.3) | .046 |
Of the 22 leukoreduced units included herein, 2 were prestorage leukoreduced; the remaining units were bedside filtered or the technique was not detailed.
ATG, anti-thymocyte globulin; ALG, anti-lymphocyte globulin; IVIg, intravenous immunoglobulin.